Drugmakers Blamed For Blocking Generics Have Jacked Up Prices And Cost U.S. Billions
The Trump administration is shaming brand-name drugmakers who refuse to sell samples so generics can be made from their products.
Drugs
981 - 1,000 of 1,305 Results
-
-
Best Reads Of The Week With Brianna Labuskes
KHN鈥檚 newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Vermont Legislators Pass A Drug Importation Law. So What?
The first-in-the-nation measure would empower Vermont to set up a wholesale program to import prescription drugs from Canada. But it still will have to get federal buy-in before it is operational.
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 Much Ado About Drug Prices
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call discuss President Donald Trump鈥檚 proposals to control prescription drug prices and the efforts to sell the plan to lawmakers and the public. Also, Rovner interviews emeritus law professor Timothy Jost about the state of the Affordable Care Act.
-
Reversing An Overdose Isn’t Complicated, But Getting The Antidote Can Be
Last month, U.S. Surgeon General Jerome Adams聽urged more Americans to carry and learn to use naloxone, which can save someone from an opioid overdose. But the drug, brand-name Narcan, can be difficult to get and expensive.
-
Trump Vows (Again) To Lower Drug Prices But Skeptics Doubt Much Will Change
President Donald Trump鈥檚 much-awaited speech about slashing drug costs was long on rhetoric but short on specifics that will reduce prices.
By Sarah Jane Tribble and Liz Szabo -
Best Reads Of The Week With Brianna Labuskes
KHN鈥檚 newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Why Did Novartis Pay Trump鈥檚 Lawyer $1.2 Million? Look At Its Drug Prices
Promises to control pharma prices threaten profits for Switzerland-based Novartis, which sells some of the costliest drugs in the world.
By Jay Hancock -
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 The Politics Of Rising Premiums And Menu Labeling
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Margot Sanger-Katz of The New York Times and Anna Edney of Bloomberg News discuss the latest on the politics of rising premiums, GOP efforts to take back money from the Children鈥檚 Health Insurance Program, and the controversy over new rules requiring calorie information on menus. Plus for extra credit, the panelists recommend their favorite health stories of the week.
-
Midterm Elections Are Shaping Up To Be A Referendum On Trumpism
Even voters who say they are more enthusiastic about voting in this congressional election than in past ones are not motivated by any specific issue. But, according to a poll out Thursday, health care policies rank high among topics voters want candidates to address.
By Rachel Bluth -
Use Of Psychiatric Drugs Soars In California Jails
A combination of factors has led to an 鈥渁stronomical鈥 increase in mentally ill inmates, followed by increased efforts to identify those who need prescriptions. Some say the meds are underprescribed; others, that they are given inappropriately, without the benefit of comprehensive treatment.
By Anna Gorman -
鈥楶harma Bro鈥 Shkreli Is In Prison, But Daraprim鈥檚 Price Is Still High
The saga of Martin Shkreli and Turing Pharmaceuticals focused a lot of attention on prescription drug prices, but no reversal of the exponential price increases for the lifesaving drug Daraprim resulted. The story offers an object lesson into the interworkings of the pharmaceutical market.
-
How A Drug Company Under Pressure For High Prices Ratchets Up Political Activity
Denmark-based drugmaker Novo Nordisk has invested more in lobbying and doubled political donations since 2015.
By Jay Hancock and Elizabeth Lucas -
Best Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes, who reads everything on health care to compile our daily Morning Briefing, offers the best and most provocative stories for the weekend.
-
Dissecting The Rhetoric Vs. Reality Of Trump鈥檚 Tough Talk On Drug Prices
President Donald Trump鈥檚 upcoming speech on drug prices comes after months of public comments and debate about tackling the issue.
-
Readers Weigh In On Vitamin Use And The Big Pharma-Patient Advocacy Connection
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
-
Must-Reads Of The Week From Brianna Labuskes
KHN鈥檚 newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 Nothing In Health Care Ever Goes Away
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Sarah Jane Tribble of Kaiser Health News, Joanne Kenen of Politico, Margot Sanger-Katz of The New York Times and Paige Winfield Cunningham of The Washington Post examine how even after Republicans failed to repeal and replace the Affordable Care Act, the health care debate continues to roil politics. They discuss how Republicans in Congress have shifted their ACA messaging and how the Democrats are looking to Medicare expansion. They also discuss state efforts to expand Medicaid and drug pricing. And they spend a moment talking about Congress鈥 push to do something about the opioid crisis.
-
Nation鈥檚 Top Doc Wants The Overdose Antidote Widely On Hand. Is That Feasible?
Surgeon General Jerome Adams urged more people to carry the drug naloxone, a lifesaving treatment for opioid overdoses. But this policy is tricky to implement.
By Shefali Luthra and Rachel Bluth -
Drug Test Spurs Frank Talk Between Hypertension Patients And Doctors
Roughly half of patients don't take their high blood pressure medicine as they should, even though heart disease is the leading cause of death in America. Now, a drug test can flag whether a patient is taking the prescribed medication and is meant to spark a more truthful conversation between patient and doctor.